Abstract Library

#3080 Impact of Multimodal Perioperative Treatment in Patients with Resected Non-Metastatic Grade 3 Neuroendocrine Neoplasms (NEN G3)

Introduction: Patients with grade 3 neuroendocrine neoplasm (NEN G3) have a limited prognosis. Even in a non-metastatic stage, the risk of recurrence after surgery is high. Multimodal perioperative treatment, including chemotherapy and/or radiotherapy in an adjuvant or neoadjuvant setting, has improved the prognosis in numerous tumor entities; however, it has not been systematically evaluated in NEN G3 so far. Nevertheless, perioperative chemotherapy is generally recommended in most current treatment guidelines for NEN G3.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Apostolidis L, Starke H, Bhatti I, Jäger D, Winkler E,

Keywords: NEN G3, neuroendocrine carcinoma, adjuvant, neoadjuvant, surgery,

#2265 Activity of Bevacizumab in Neuroendocrine Neoplasms

Introduction: The combination of the anti-VEGF antibody bevacizumab (BEV) with a multitude of other antineoplastic substances has shown promising activity in neuroendocrine neoplasms (NEN). However, data proving the superiority of BEV-containing vs. BEV-free protocols are lacking.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Apostolidis L

Authors: Fejzibegovic N, Jäger D, Winkler E, Apostolidis L,

Keywords: neuroendocrine neoplasm, targeted therapy, bevacizumab, antiangiogenesis,

#2259 Clinical Characteristics, Treatment Outcomes and Potential Novel Therapeutic Options for Patients with Prostatic Neuroendocrine Carcinoma

Introduction: Prostatic neuroendocrine carcinomas (PNECs) are rare tumors with poor prognosis. While platinum and etoposide based chemotherapy regimens (PE) are commonly applied in first-line for advanced disease, clinical-grade evidence for treatment options in second-line and beyond is very limited.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Apostolidis L, Nientiedt C, Winkler E, Stenzinger A, Duensing S,

Keywords: neuroendocrine carcinoma, prostate, chemotherapy, immunotherapy,

#2250 Treatment Outcomes of Patients with Mixed Neuroendocrine Non-Neuroendocrine Neoplasms (MiNEN)

Introduction: Mixed neuroendocrine non-neuroendocrine neoplasms (MiNEN) have been newly defined in the WHO 2017 classification. They are rare tumors, commonly treated in analogy to their non-neuroendocrine (nNE) or neuroendocrine (NE) component without systematic data regarding the optimal therapeutic strategy.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Apostolidis L, Bergmann F, Haag G, Jäger D, Winkler E,

Keywords: MiNEN, mixed neuroendocrine non-neuroendocrine neoplasm, MANEC, mixed adenoneuroendocrine carcinoma,

#2090 Financial Toxicity in Patients with Neuroendocrine Tumor Disease. A so far Underestimated "Side Effect" of Cancer in Germany?

Introduction: Cancer is not only associated with physical and psychological, but also financial burden. In contrast to other countries, the socio-economic impact of cancer for patients in Germany, with a third party paid health care system, is poorly understood.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Winkler E, Mehlis K, Kudlich M, Apostolidis L, Witte J,

Keywords: financial toxicity, economic burden, patient-reported outcome, distress, quality of life,